Literature DB >> 14558669

Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.

S Ohta1, S Nishizawa, Y Oki, T Yokoyama, H Namba.   

Abstract

Biologically inactive ACTH-producing pituitary adenoma is known as clinically silent corticotroph adenoma. To search for the mechanism causing clinically silent corticotroph adenoma, we immunohistochemically examined the expression of prohormone convertase 1/3 (PC1/3) in this type of adenoma and compared our results with those obtained for Cushing's disease. All of the Cushing's disease specimens exhibited strongly positive PC1/3 exhibition. On the contrary, the expression of PC1/3 was very weak in the clinically silent corticotroph adenoma specimens. The absence of PC1/3 in clinically silent corticotroph adenoma indicates that silent corticotroph adenomas arise in a different cell type sharing the prohormone pro-opiomelanocortin (POMC), but processing it differently, accounting for the lack of clinical symptoms due to ACTH excess.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14558669     DOI: 10.1023/a:1025321731790

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  12 in total

1.  Cdc6 expression as a marker of proliferative activity in brain tumors.

Authors:  S Ohta; M Koide; T Tokuyama; N Yokota; S Nishizawa; H Namba
Journal:  Oncol Rep       Date:  2001 Sep-Oct       Impact factor: 3.906

2.  Large and invasive silent corticotroph-cell adenoma with elevated serum ACTH: a case report.

Authors:  T Ueyama; N Tamaki; T Kondoh; H Kurata
Journal:  Surg Neurol       Date:  1998-07

3.  Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study.

Authors:  E Horvath; K Kovacs; D W Killinger; H S Smyth; M E Platts; W Singer
Journal:  Am J Pathol       Date:  1980-03       Impact factor: 4.307

4.  What can predict postoperative "endocrinological cure" in Cushing's disease?

Authors:  S Nishizawa; Y Oki; S Ohta; N Yokota; T Yokoyama; K Uemura
Journal:  Neurosurgery       Date:  1999-08       Impact factor: 4.654

5.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

6.  A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome.

Authors:  H Raff; J W Findling
Journal:  Clin Chem       Date:  1989-04       Impact factor: 8.327

7.  Analysis of endocrine active and clinically silent corticotropic adenomas by in situ hybridization.

Authors:  R V Lloyd; K Fields; L Jin; E Horvath; K Kovacs
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

8.  Localization of prohormone convertases 1/3 and 2 in the human pituitary gland and pituitary adenomas: analysis by immunohistochemistry, immunoelectron microscopy, and laser scanning microscopy.

Authors:  I Takumi; D F Steiner; N Sanno; A Teramoto; R Y Osamura
Journal:  Mod Pathol       Date:  1998-03       Impact factor: 7.842

9.  Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic human tissues: their use as markers of neuroendocrine differentiation.

Authors:  L Scopsi; M Gullo; F Rilke; S Martin; D F Steiner
Journal:  J Clin Endocrinol Metab       Date:  1995-01       Impact factor: 5.958

10.  Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries.

Authors:  R V Lloyd; L Jin; X Qian; B W Scheithauer; W F Young; D H Davis
Journal:  Am J Pathol       Date:  1995-05       Impact factor: 4.307

View more
  16 in total

Review 1.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

2.  The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.

Authors:  Alberto Righi; Marco Faustini-Fustini; Luca Morandi; Valentina Monti; Sofia Asioli; Diego Mazzatenta; Antonella Bacci; Maria Pia Foschini
Journal:  Endocrine       Date:  2016-08-04       Impact factor: 3.633

Review 3.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

4.  Perioperative hypothalamic pituitary adrenal function in patients with silent corticotroph adenomas.

Authors:  Abdelle F Cheres; Nadine ElAsmar; Aman Rajpal; Warren R Selman; Baha M Arafah
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

Review 5.  Silent corticotroph adenomas.

Authors:  Odelia Cooper
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

6.  Cushing's disease arising from a clinically nonfunctioning pituitary adenoma.

Authors:  Luiz Roberto Salgado; Márcio Carlos Machado; Arthur Cukiert; Bernardo Liberman; Cristina Takami Kanamura; Venancio Avancini Ferreira Alves
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

7.  Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.

Authors:  Odelia Cooper; Anat Ben-Shlomo; Vivien Bonert; Serguei Bannykh; James Mirocha; Shlomo Melmed
Journal:  Horm Cancer       Date:  2010-04       Impact factor: 3.869

Review 8.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

9.  Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.

Authors:  Kazumi Iino; Yutaka Oki; Fumie Matsushita; Miho Yamashita; Chiga Hayashi; Katsutoshi Miura; Shigeru Nishizawa; Hirotoshi Nakamura
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

10.  Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas.

Authors:  Laura Sanchez-Tejada; Ruth Sanchez-Ortiga; Cristina Lamas; Rosa Camara; Pedro Riesgo; Carmen Fajardo; Francisco Ignacio Aranda; Antonio Pico
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.